



FOR IMMEDIATE RELEASE

ImmusanT Announces Presentations at Digestive Disease Week 2016

- Celiac Disease Satellite Symposium to be Held Sunday, May 22, 2016 -

CAMBRIDGE, Mass. – May 19, 2016 – ImmusanT, Inc., a company developing Nexvax2®, a therapeutic vaccine designed to protect against the effects of gluten exposure in HLA-DQ2.5+ patients with celiac disease, today announced two poster presentations and one oral presentation that will take place at Digestive Disease Week 2016, being held from Saturday, May 21 to Tuesday, May 24, 2016 at the San Diego Convention Center in San Diego, California. The company also announced that it will host a satellite symposium titled, “New Developments in Celiac Disease: The Promise of Disease-Modifying Immune Tolerance Therapy” on Sunday, May 22, 2016 at the Manchester Grand Hyatt Hotel in San Diego, California. The satellite symposium is not affiliated with Digestive Disease Week.

Details of the presentations are as follows:

Date: Saturday, May 21, 2016
Time: 9:30 AM – 4:00 PM PDT
Location: Hall C, San Diego Convention Center
Poster Session: Celiac Disease (I)
Abstract Number: Sa1395
Title: Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People with Celiac Disease (CeD)

Date: Saturday, May 21, 2016
Time: 9:30 AM – 4:00 PM PDT
Location: Hall C, San Diego Convention Center
Poster Session: Celiac Disease (I)
Abstract Number: Sa1396
Title: A Single Intradermal (ID) Injection of Nexvax2®, a Peptide Composition with Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People with Celiac Disease (CeD)

Date: Tuesday, May 24, 2016
Time: 9:00 – 9:15 AM PDT
Location: Room 33, San Diego Convention Center
Session: Celiac-Clinical: Updates on Management of Celiac Disease
Abstract Number: 846
Title: Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD)

Details of the satellite symposium are as follows:

Date: Sunday, May 22, 2016
Time: 6:00 – 9:00 PM PDT
Location: Harbor Ballroom A, Manchester Grand Hyatt San Diego
Title: New Developments in Celiac Disease: The Promise of Disease-Modifying Immune Tolerance Therapy

About ImmusanT Inc.

ImmusanT is a privately held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing [Nexvax2](#)[®], a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by [Vatera Healthcare Partners](#). More information may be found at www.immusant.com, or follow [ImmusanT](#) on Twitter.

ImmusanT Contact:

Leslie Williams
President and CEO
(617) 299-8399 Ext. 201
Leslie@ImmusanT.com

Media Contact:

Casey Doucette, PhD
MacDougall Biomedical Communications
(781) 235-3060
cdoucette@macbiocom.com

###